Identification of Predictors of Non-alcoholic Steatohepatitis and Its Severity in Individuals Undergoing Bariatric Surgery

被引:2
作者
Ayres, Arthur Balestra Silveira [1 ]
Carneiro, Carollyne Rodovalho Guerra [1 ]
Gestic, Martinho Antonio [1 ]
Utrini, Murillo Pimentel [1 ]
Chaim, Felipe David Mendonca [1 ]
Callejas-Neto, Francisco [1 ]
Chaim, Elinton Adami [1 ]
Cazzo, Everton [1 ,2 ]
机构
[1] State Univ Campinas UNICAMP, Sch Med Sci, Dept Surg, Rua Alexander Fleming S-NO, BR-13085000 Campinas, SP, Brazil
[2] Cidade Univ Zeferino Vaz, BR-13085000 Campinas, SP, Brazil
关键词
Non-alcoholic fatty liver disease; Fatty liver; Obesity; Bariatric surgery; Liver function tests; FATTY LIVER-DISEASE; AMERICAN ASSOCIATION; CARDIOVASCULAR RISK; DIABETES-MELLITUS; FIBROSIS; PREVALENCE; MANAGEMENT; MORTALITY; DIAGNOSIS; FERRITIN;
D O I
10.1007/s11695-023-06986-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background As obesity reached epidemic proportions, non-alcoholic fatty liver disease (NAFLD) also had a worrisome parallel increase. The non-invasive differentiation of non-alcoholic steatohepatitis (NASH) from uncomplicated NAFLD remains an important challenge in current clinical practice.Objective To identify predictors of the occurrence and severity of NAFLD and NASH.Methods This is an analytical cross-sectional study which included individuals undergoing bariatric surgery. Participants were histologically classified according to the presence NASH and severity of NAFLD. Demographic, clinical, anthropometric, and biochemical aspects were analyzed and compared.Results Out of 171 individuals, 87.7% were female and the mean age was 38.4 +/- 9.3 years. The average BMI was 38 +/- 3.0 kg/m(2). NAFLD was histologically confirmed in 74.9%; the commonest histopathological abnormalities were macrovesicular steatosis (74.9%) and ballooning (40.4%). Simple steatosis occurred in 30.4%, 44.4% presented with NASH, and 31% had severe NAFLD. NASH associated with higher levels of ALT (0.03), ALP (0.02), and glucose (0.02). Cutoff values were, respectively, 23 U/L, 67 U/L, and 81 mg/dL. Their concomitant use provided an 83.1% specificity for NASH. Severe NAFLD associated with diabetes (p=0.02), higher BMI (p=0.01), AST (p=0.04), ALT (p<0.01), ALP (p=0.01), glucose (p=0.02), and ferritin (p<0.01). BMI over 39.3 kg/m(2) and ferritin over 178 ng/mL concomitantly provided a 70.5% accuracy for severe NAFLD.Conclusions NASH and severe NAFLD associated with higher levels of ALT, ALP, and glucose. Severe NAFLD associated with higher BMI and higher ferritin levels in this group. The concomitant evaluation of these laboratory tests could help ruling out NASH and safely screening severe NAFLD.
引用
收藏
页码:456 / 466
页数:11
相关论文
共 65 条
[1]   Current treatment of non-alcoholic fatty liver disease [J].
Ahmed, Mohamed H. ;
Byrne, Christopher D. .
DIABETES OBESITY & METABOLISM, 2009, 11 (03) :188-195
[2]   Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease [J].
Alexopoulos, Anastasia-Stefania ;
Crowley, Matthew J. ;
Wang, Ying ;
Moylan, Cynthia A. ;
Guy, Cynthia D. ;
Henao, Ricardo ;
Piercy, Dawn L. ;
Seymour, Keri A. ;
Sudan, Ranjan ;
Portenier, Dana D. ;
Diehl, Anna Mae ;
Coviello, Andrea D. ;
Abdelmalek, Manal F. .
HEPATOLOGY, 2021, 74 (03) :1220-1233
[4]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[5]   Long-Term Mortality in Nonalcoholic Fatty Liver Disease: Is Liver Histology of Any Prognostic Significance? [J].
Angulo, Paul .
HEPATOLOGY, 2010, 51 (02) :373-375
[6]   Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block [J].
Athyros, Vasilios G. ;
Polyzos, Stergios A. ;
Kountouras, Jiannis ;
Katsiki, Niki ;
Anagnostis, Panagiotis ;
Doumas, Michael ;
Mantzoros, Christos S. .
CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (02) :172-181
[7]   Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis [J].
Athyros, Vasilios G. ;
Katsiki, Niki ;
Doumas, Michael .
CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (02) :104-106
[8]   The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement [J].
Athyros, Vasilios G. ;
Alexandrides, Theodore K. ;
Bilianou, Helen ;
Cholongitas, Evangelos ;
Doumas, Michael ;
Ganotakis, Emmanuel S. ;
Goudevenos, John ;
Elisaf, Moses S. ;
Germanidis, Georgios ;
Giouleme, Olga ;
Karagiannis, Asterios ;
Karvounis, Charalambos ;
Katsiki, Niki ;
Kotsis, Vasilios ;
Kountouras, Jannis ;
Liberopoulos, Evangelos ;
Pitsavos, Christos ;
Polyzos, Stergios ;
Rallidis, Loukianos S. ;
Richter, Dimitrios ;
Tsapas, Apostolos G. ;
Tselepis, Alexandros D. ;
Tsioufis, Konstantinos ;
Tziomalos, Konstantinos ;
Tzotzas, Themistoklis ;
Vasiliadis, Themistoklis G. ;
Vlachopoulos, Charalambos ;
Mikhailidis, Dimitri P. ;
Mantzoros, Christos .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 71 :17-32
[9]   Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update [J].
Athyros, Vasilios G. ;
Tziomalos, Konstantinos ;
Katsiki, Niki ;
Doumas, Michael ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (22) :6820-6834
[10]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109